Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | AK112 |
Trade Name | |
Synonyms | AK 112|AK-112 |
Drug Descriptions |
AK112 is a bispecific antibody that binds PD-1 and VEGFA, potentially resulting in decreased tumor growth (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2515). |
DrugClasses | Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 101 VEGFA Antibody 3 |
CAS Registry Number | NA |
NCIT ID | C170909 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AK112 | AK112 | 0 | 1 |
AK112 + Carboplatin + Paclitaxel | AK112 Carboplatin Paclitaxel | 0 | 0 |
AK112 + Carboplatin + Pemetrexed Disodium | AK112 Carboplatin Pemetrexed Disodium | 0 | 0 |
AK112 + Docetaxel | AK112 Docetaxel | 0 | 0 |